Spirometric assessment of emphysema presence and severity as measured by quantitative CT and CT-based radiomics in COPD by Occhipinti, M. et al.
RESEARCH Open Access
Spirometric assessment of emphysema
presence and severity as measured by
quantitative CT and CT-based radiomics
in COPD
Mariaelena Occhipinti1* , Matteo Paoletti1, Brian J. Bartholmai2, Srinivasan Rajagopalan3, Ronald A. Karwoski3,
Cosimo Nardi4, Riccardo Inchingolo5, Anna R. Larici6, Gianna Camiciottoli1, Federico Lavorini1, Stefano Colagrande2,
Vito Brusasco7 and Massimo Pistolesi1
Abstract
Background: The mechanisms underlying airflow obstruction in COPD cannot be distinguished by standard
spirometry. We ascertain whether mathematical modeling of airway biomechanical properties, as assessed
from spirometry, could provide estimates of emphysema presence and severity, as quantified by computed
tomography (CT) metrics and CT-based radiomics.
Methods: We quantified presence and severity of emphysema by standard CT metrics (VIDA) and co-registration
analysis (ImbioLDA) of inspiratory-expiratory CT in 194 COPD patients who underwent pulmonary function testing.
According to percentages of low attenuation area below − 950 Hounsfield Units (%LAA-950insp) patients were classified
as having no emphysema (NE) with %LAA-950insp < 6, moderate emphysema (ME) with %LAA-950insp≥ 6 and < 14, and
severe emphysema (SE) with %LAA-950insp≥ 14. We also obtained stratified clusters of emphysema CT features by an
automated unsupervised radiomics approach (CALIPER). An emphysema severity index (ESI), derived from
mathematical modeling of the maximum expiratory flow-volume curve descending limb, was compared with
pulmonary function data and the three CT classifications of emphysema presence and severity as derived
from CT metrics and radiomics.
Results: ESI mean values and pulmonary function data differed significantly in the subgroups with different
emphysema degree classified by VIDA, ImbioLDA and CALIPER (p < 0.001 by ANOVA). ESI differentiated NE
from ME/SE CT-classified patients (sensitivity 0.80, specificity 0.85, AUC 0.86) and SE from ME CT-classified
patients (sensitivity 0.82, specificity 0.87, AUC 0.88).
Conclusions: Presence and severity of emphysema in patients with COPD, as quantified by CT metrics and
radiomics can be estimated by mathematical modeling of airway function as derived from standard spirometry.
Keywords: Pulmonary emphysema, COPD, Small airway disease, Respiratory function tests, Spirometry, Tomography,
Radiomics, Area under curve
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Background
Chronic obstructive pulmonary disease (COPD) is a
complex condition with a wide spectrum of clinical pre-
sentations and pathological features unified under the
spirometric definition of airflow obstruction. Airway nar-
rowing and parenchymal destruction are recognized as
the mechanisms responsible for airflow obstruction in
COPD, but they cannot be distinguished by standard
spirometry. However, standard spirometry is one of the
most employed variables for patients enrollment and
outcome evaluation in clinical and pharmacologic
studies.
In recent years, chest computed tomography (CT) al-
lows to depict and measure in vivo the lung pathologic
changes of COPD by quantifying parenchymal destruc-
tion, the direct sign of emphysema, as well as bronchial
wall thickening and gas trapping, which represent direct
and indirect signs of conductive airway disease, respect-
ively [1, 2]. A closer imaging definition of whether con-
ductive airway disease or emphysema is the predominant
mechanism of airflow obstruction has been lately obtained
by using co-registration analysis of inspiratory and expira-
tory CT scans [3]. Nowadays more information is ex-
tracted from imaging data using advanced feature analysis
representing what is called “radiomics” [4]. Artificial
neural networks and statistical models are available to
provide radiologists and clinicians with objective and
reproducible computer-based evaluations of lung par-
enchyma. In particular, CALIPER (Computer Aided
Lung Informatics for Pathology Evaluation and Rating)
recently developed at Mayo Clinic (Rochester, MN), is a
computational platform for the near real-time
characterization and quantification of lung parenchy-
mal patterns on CT scan [5, 6].
Altogether, quantitative and qualitative studies have
shown that CT can allow distinguishing not only be-
tween airway and parenchymal abnormalities, but also
between subtypes of emphysema, i.e. centrilobular, pan-
lobular, and paraseptal [7]. However, a widespread rou-
tine use of CT for the assessment of COPD in clinical
practice and clinical and pharmacologic studies cannot
be currently foreseen due to radiation exposure and lim-
ited instrumental availability in the face of the COPD
rapidly increasing prevalence of the disease [8].
In a previous study we have shown that a probabilistic
model based on body mass index, FEV1 as percent of
predicted, FEV1/VC and DLco as percent of predicted
could be used to estimate emphysema quantified on CT
[9]. Limitations of that approach for clinical practice or
clinical and pharmacologic trials are that DLco is not al-
ways available and that standard pulmonary function pa-
rameters have a wide inter-individual variability, even
after normalization for ethnicity, age, and body size [10].
Furthermore, probabilistic models rely on regression
coefficients that reflect the characteristics of the training
set. These limitations may be possibly overcome by math-
ematical models studying directly the biomechanical char-
acteristics of airway function of each patient [11].
The aim of the present study was to assess whether a
mathematical model designed to fit the shape of the
maximum expiratory flow-volume curve (MEFV) ob-
tained by standard spirometry could provide estimates of
the presence and the severity of emphysema comparable
with parameters used to assess emphysema extent de-
rived from quantitative CT and CT-based radiomics.
Methods
This prospective two-center study was approved by the
institutional Ethics Committees of the University of Flor-
ence and of the Catholic University of Sacred Heart in
Rome. The study is based on a retrospective interpret-
ation of prospectively acquired data. From January 2012
to December 2016, subjects with diagnosis of COPD
(post-bronchodilator FEV1/VC < 0.70) [12, 13] were con-
sidered for inclusion if they satisfied the following inclu-
sion criteria: age 40–85 years, smoking history > 10
pack-years, no COPD exacerbations within 1 month, no
diagnosis of cardiac disease, and acceptance to partici-
pate by written informed consent. Patients with a revers-
ible airflow obstruction greater than 12% and 200 ml
after inhalation of bronchodilator (according to ATS
recommendations) or those with a clinical history of
present or previous asthma episodes were excluded [12,
14]. Thirty-eight out of 232 eligible subjects were ex-
cluded because of incomplete data or coexisting abnor-
malities on CT scan.
Functional evaluation
Subjects underwent complete pulmonary function evalu-
ation by using a mass-flow sensor and multigas analyser
(V6200 Autobox Body Plethysmograph Sensor Medics,
Yorba Linda, CA, USA, or Platinum Elite™ Body Ple-
thysmograph, Medical Graphics Corporation, St. Paul,
MN, USA), arterial blood gases by Radiometer ABL90
FLEX or ABL800 FLEX (Brønshøj, Denmark). Pre- and
post-bronchodilator spirometry, lung volumes, and
single-breath DLco were obtained according to standard
ATS/ERS (American Thoracic Society/European Re-
spiratory Society) recommendations [15].
CT scanning technique and analysis
In each center volumetric chest CT scans were obtained
by the same team and the same CT scanner (SOMATOM
Sensation 64 or SOMATOM Definition FLASH 128,
Siemens, Erlangen, Germany) within 48 h of the functional
evaluation. CT scans were acquired at full inspiration and
forced end-expiration using the acquisition protocol
adopted in the COPDGene Study [16] with the following
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parameters: 120 kVp, 200 mAs, rotation time 0.5 s, slice
thickness 0.6 mm, pitch 1.1 and reconstructions kernels
b31f (smooth) and b70f (sharp). The same personnel care-
fully trained all subjects before undergoing CT scans for
consistency in CT data acquisition. Subjects were
instructed on how to perform respiratory maneuvers while
lying supine in the CT scanner with arms fully abducted.
No contrast medium was injected. Post-processing image
analysis was performed on images with reconstruction
kernel b31f by using three different software programs:
VIDA, Imbio LDA, CALIPER (Fig. 1a-f).
– VIDA analysis (Fig. 1b). We used the Pulmonary
Workstation Apollo 2.1 (VIDA, Coralville, IA, USA)
installed onsite to segment airways and lungs and to
calculate the relative volumes of lung attenuation
area with values below − 950 Hounsfield Units (HU)
at inspiration (%LAA-950insp) and below -856HU at
expiration (%LAA-856exp). Thresholds at − 950 HU
and -856HU were chosen as densitometric cut-offs
for emphysema and total gas trapping, respectively
[1, 17, 18]. The analysis was fully automated with
the possibility to correct manually any mistake in
Fig. 1 Lung parenchyma representations at CT scan after post-processing with different software programs in a patient with severe emphysema.
a. Axial CT scan shows advanced destructive emphysema with a giant bulla in the right lower lobe adjacent to an area of passive atelectasis. b.
Volume rendering of the densitometric analysis performed by VIDA shows the location and severity of emphysema at inspiratory scan (threshold
-950HU) displaying spheres whose diameter is proportional to the relative volume of emphysema in each region. c-d. Coronal and Sagittal 2D
images obtained by co-registration of inspiratory and expiratory CT scans by Imbio LDA show the location of emphysema (red), functional airways
gas trapping (yellow), and normal lung (green). e. Volume rendering of the lung texture analysis performed by CALIPER shows the 3D distribution
of the different lung patterns, including Normal (dark green), Mild Low Attenuation Area (LAA, light green), Moderate LAA (light blue), Severe LAA
(dark blue), Ground-glass (yellow), Reticular (orange). The glyph f provided by CALIPER summarizes the location and amount of the different lung
patterns. The overall area of the glyph represents the computed total lung volume, the partitions with thick radial lines illustrate the relative
volumes of the left (L) and right (R) lungs, which are further divided with thin radial lines into three regions, each representing the upper (U),
middle (M), lower (L) lung zones. In this patient severe LAA dominates in the right lower and middle lung zones, whereas middle and lower left
zones are characterized by mild and moderate LAA
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airway or lobe segmentation. Bronchial wall
thickening was calculated as airway wall thickness
at an internal perimeter of 10mm (AWTPi10) [19].
– Imbio LDA analysis (Fig. 1c-d). Co-registration
analysis performed by Imbio LDA (Minneapolis,
MN, US) automatically pairs inspiratory and
expiratory CT scans to provide percentages of
normal lung (percentage of voxels with CT
attenuation greater than − 950 HU at inspiration
and greater than -856HU at expiration), persistent
low density area (%pLDA, voxels with CT attenuation
below -950HU at inspiration and below -856HU at
expiration), and functional low density area (%fLDA,
voxels with CT attenuation above -950HU at
inspiration and below -856HU at expiration) [3].
%fLDA represents the non-emphysematous
contribution to total gas trapping, namely the
fraction of gas trapped at end expiration because
of airway closure or extreme flow limitation.
Moreover, Imbio LDA provides parametric response
maps showing the regional distribution of each lung
pattern. The analysis was fully automated and
performed on an online platform called Imbio
Launchpad.
– CALIPER analysis (Fig. 1e-f ). Inspiratory CT scans
were post-processed by using CALIPER (Mayo
Clinic, Rochester, MN, USA), a computational
platform for the near real-time characterization and
quantification of seven lung parenchymal patterns
on CT scans, including Normal, Mild Low
Attenuation Area (LAA), Moderate LAA, Severe
LAA, Ground-glass, Reticular, and Honeycombing
(Fig. 1e) [5]. CALIPER is based on histogram
signature mapping techniques trained through
expert radiologist consensus assessment of
pathologically confirmed datasets obtained
through the Lung Tissue Research Consortium
[6, 20]. For each subject, CALIPER outputs a
glyph similar to a radial space-filling plot providing
an iconic summary of the volumetric parenchymal
classification, thus facilitating the comprehension of
the multidimensional source data [6]. The area of the
glyph represents the computed total lung volume.
The glyph is partitioned with radial lines to illustrate
the relative volumes of the left and right lungs and
further divided into three regions, each representing
the upper/middle/lower lung zones (Fig. 1f ).
CALIPER analysis was fully automated and was
performed onsite in the laboratory.
Emphysema Severity Index (ESI)
ESI is based on a parametric biomechanical model
representing a theoretical approximation of the shape of
the descending limb of the MEFV curve computed by
assuming that at a given time the pressure lost by a fluid
flow conveyed in a cylindrical duct is inversely related to
its diameter and directly related to the fluid specific fric-
tion factor, density, and velocity (see the Additional file
1 for theoretical and mathematical details). The compu-
tation does not require standardization of input parame-
ters, as it is directly related to the shape of the curve.
Therefore, ESI is independent from percentage predicted
values of pulmonary function variables. ESI value was
computed in each patient using a specifically developed
software application, whose theoretical basis is reported
on the online supplement. A numerical output value
ranging from 0 to 10 was used to stratify the dataset of
194 COPD patients according to the estimated emphy-
sema severity.
Data analysis and statistics
The relationship between ESI scores, functional data and
CT metrics was assessed by Pearson correlation coeffi-
cients. Robust Steiger’s Z-test was used to evaluate the
statistical significance of differences in correlations be-
tween CT-metrics relative to emphysema (%LAA-950insp
and %pLDA) and ESI, FEV1%, and FEV1/FVC.
By using the two thresholds of %LAA-950insp reported in
literature to define absence of significant emphysema (6%)
[7] and severe emphysema (14%) [21] we classified the pa-
tients in three subgroups: no emphysema (NE, %LAA-950insp
< 6), moderate emphysema (ME, 6 ≤%LAA-950insp < 14), and
severe emphysema (SE, %LAA-950insp ≥ 14).
A pairwise dissimilarity matrix was derived using SILA
(Scale Indicative of Lung parenchyma Abnormality).
SILA between a pair of CALIPER quantified CT lung
volumes was computed as a cumulative aggregate of the
differentials of normalized distributions of ordered (as
mild, moderate, and severe) CALIPER exemplars. The
unique clusters representing similar groups of patients
were identified by unsupervised clustering of the 194 ×
194 dissimilarity matrix using affinity propagation. The
method does not require an a priori specification of the
number of desired clusters.
Chi-squared test was used to determine any significant
differences between expected and observed frequencies
in the clusters obtained by CALIPER and the three
groups defined on the basis of %LAA-950insp ranges (NE,
ME, SE).
Analysis of variance, Welch’s t, and Games-Howell
post-hoc tests were used to evaluate differences of the
mean values of pulmonary function tests and ESI mean
values among the three groups of emphysema severity
defined by VIDA and Imbio LDA, as well as the clusters
obtained by CALIPER.
To evaluate the performances of the ESI software as a
classification tool we used logistic regression analysis. In
each patient we estimated the probability of being
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affected by “severe” emphysema (%LAA-950insp ≥ 14, data
computed by VIDA) given the ESI value obtained by
spirometry. In a similar manner we estimated the prob-
ability of “absence” of significant emphysema
(%LAA-950insp < 6, data computed by VIDA) given the
ESI value.
A ten-fold cross validation was performed over the en-
tire dataset and we calculated the True Positives and
False Positives rates for each fold. Sensitivity, specificity
and AUC were evaluated by ROC curve analysis. In par-
ticular we estimated in each patient the probability of
being affected by “severe” emphysema (%LAA-950insp
≥14, data provided by VIDA) given the value of ESI
score obtained by spirometry; π = Pr (Y = “Severe” | X =
ESI) and the probability of “absence” of emphysema
(%LAA-950insp < 6, data provided by VIDA) given the
value of ESI score obtained by spirometry; π = Pr (Y
= “Absence” | X = ESI).
The software programs included Mathcad (version
2001; Mathsoft), SPSS/PC WIN 11.5.1 (SPSS, Chicago,
IL), C++ programming language, and Orange [22].
Values of p lower than 0.05 indicated statistical signifi-
cance. Data are expressed as mean and standard devi-
ation (SD).
Results
Table 1 describes anthropometric, pulmonary function,
and CT metrics data of the 194 subjects included in the
study. Subjects were distributed across all GOLD stages:
55 stage I, 62 stage II, 56 stage III, and 21 stage IV.
Figure 1 shows CT images of a patient with advanced
destructive emphysema before (Fig. 1a) and after
post-processing image analysis by using the three differ-
ent software programs: VIDA (Fig. 1b), Imbio LDA (Fig.
1c-d), and CALIPER (Fig. 1e-f ).
Figure 2 illustrates the patients subdivision according
to the pairwise dissimilarity matrix that identified three
clusters (G1-G3), based on the SILA metric derived
from the features extracted by CALIPER. Cluster G1
consisted of 95/194 (49%) subjects, G2 of 65/194 (33.5%)
subjects, and G3 of 34/194 (17.5%) subjects. Across the
three different clusters patients lungs were represented
by a glyph, illustrating the regional composition of clas-
sified lung volume with color-coded sections propor-
tional to the percentage of lung patterns within the
region (Fig. 1f ). G1 was characterized by predominant
Normal and Mild LAA patterns, G2 by predominant
Moderate LAA pattern, and G3 by predominant Severe
and Moderate LAA patterns. Patients clustered as G1 by
CALIPER had either NE or ME at VIDA, whereas pa-
tients clustered as G2 had ME or SE and all patients
clustered as G3 had SE.
Table 2 shows the correlations between ESI values and
functional and radiological data. The strongest correlations
were seen between ESI and FEV1/FVC (r = − 0.87) and be-
tween ESI and %LAA-950insp(r = 0.81) or %pLDA (r = 0.80).
The correlation between ESI values and AWTPi10 was not
significant (r = 0.13). Table 3 shows the correlation between
CT metrics and ESI, FEV1 and FEV1/FVC. CT metrics of
emphysema (%LAA-950insp and %pLDA) correlated more
strongly with ESI (r = 0.81 and 0.80) than with FEV1 (r = −
0.50 and − 0.52) and FEV1/FVC (r = − 0.67 and − 0.68). Dif-
ferences in r values were statistically significant (p < .001).
Table 4 displays the mean values of ESI and the func-
tional data of the three groups of patients stratified by
quantitative CT (VIDA, Imbio LDA) according to the
thresholds to define different degrees of emphysema
(NE, ME, SE) and by radiomics (CALIPER) according to
the clusters of progressive emphysema severity (G1, G2,
G3). Patients allocation differed within the three groups
defined by each of the quantitative CT post-processing
techniques. However, a significant progressive impair-
ment from patients classified NE or G1 to patients clas-
sified SE and G3 was observed. Pulmonary function data
were significantly different among the subgroups with
various degrees of emphysema with a few exceptions
(Table 5). Lower ESI values (< 5) were typical for MEFV
Table 1 Anthropometric, pulmonary function and CT metrics
data of the 194 COPD subjects included in the study
Sex (M:F) 154:40
Age (yr) 70 (8.0)
BMI (kg/m2) 27 (4.6)
Smoking history (pack-years) 52 (27)
FEV1 (% pred) 63 (26)
FEV1/VC 48 (13)
FEV1/FVC 52 (13)
TLC (% pred) 108 (17)
DLco (% pred) 69 (24)
RV (% pred) 137 (47)
FRC (% pred) 130 (33)
RV/TLC 50 (14)
VIDA %LAA-950insp 14 (12)
%LAA-856exp 45 (20)
Imbio LDA %pLDA 12.2 (12.5)
%fLDA 37.1 (14.0)
% Normal 49.1 (21.1)
Data are expressed as mean (SD). Legend: BMI body mass index, DLco
diffusing lung capacity for carbon monoxide, FEV1% forced expiratory volume
in 1 s, %fLDA percentage of functional low density area, FRC functional residual
capacity, FVC forced vital capacity, %LAA-950insp percentage of lung attenuation
area with values <− 950 Hounsfield Units at inspiratory CT scan, %LAA-856exp
percentage of lung attenuation area with values <−856 Hounsfield Units at
expiratory CT scan, % Normal percentage of normal lung, %pLDA percentage
of persistent low density area, %pred percentage of predicted, RV residual
volume, TLC total lung capacity, VC vital capacity
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curves obtained in COPD patients with NE or ME,
whereas higher values (> 5) were observed in patients
with SE. Mean of the ESI values differed significantly
among the three emphysema groups defined by
%LAA-950insp by VIDA (p < .001) as well as among the
three Imbio LDA groups (p < .001) and CALIPER clus-
ters (p < .001).
As FEV1 and FEV1/FVC differed significantly between
groups with various degrees of emphysema (NE, ME,
SE) we performed a ROC analysis (see ROC curves in
Fig. 2 The three clusters of COPD patients stratified represented as glyphs. Clusters (G1 to G3) were the result of quantitative unsupervised
clustering based on a dissimilarity matrix that captures the distribution of classified parenchymal patterns recognized by CALIPER. G1 was
characterized by predominant Normal (dark green) and Mild LAA (light green) patterns, whereas G2 by predominant Moderate LAA (light blue)
pattern and G3 by predominant Severe (dark blue) and Moderate LAA (light blue) patterns
Table 2 Pearson r correlations between ESI scores and
functional and radiological data
ESI
r p
%LAA-950insp 0.81 <.01
%LAA-856exp 0.74 <.01
%fLDA 0.46 <.01
%pLDA 0.80 <.01
AWTPi10 0.13 .09
FEV1 (%pred.) −0.74 <.01
FVC (%pred) − 0.30 <.01
FEV1/FVC (%) −0.87 <.01
FRC (% pred) 0.69 <.01
RV (% pred) 0.65 <.01
TLC (% pred) 0.37 <.01
DLco (% pred) −0.56 <.01
Legend: AWTPi10 airway wall thickness at an internal perimeter of 10mm,
DLco diffusing lung capacity for carbon monoxide, FEV1 forced expiratory
volume in 1 s, %fLDA percentage of functional low density area, FRC forced
respiratory capacity, FVC forced vital capacity, %LAA-950insp percentage of lung
attenuation area with values <− 950 Hounsfield Units at inspiratory CT scan,
%LAA-856exp percentage of lung attenuation area with values <− 856 Hounsfield
Units at expiratory CT scan, %pLDA percentage of persistent low density area,
%pred percentage of predicted, RV residual volume, TLC total lung capacity
Table 3 Pearson r correlations between CT metrics and FEV1,
FEV1/FVC, ESI scores
FEV1/FVC FEV1% ESI
r p r p r p
%LAA-950insp −0.67 <.01 −0.50 <.01 0.81 <.01
%LAA-856exp −0.71 <.01 −0.58 <.01 0.74 <.01
AWTPi10 −0.11 .11 −0.22 <.01 0.13 .09
%fLDA −0.49 <.01 −0.42 <.01 0.46 <.01
%pLDA −0.68 <.01 −0.52 <.01 0.80 <.01
Legend: AWTPi10 airway wall thickness at an internal perimeter of 10mm, ESI
emphysema severity index, FEV1% forced expiratory volume in 1 s, %fLDA
percentage of functional low density area, FVC forced vital capacity, %
LAA-950insp percentage of lung attenuation area with values <− 950 Hounsfield
Units at inspiratory CT scan, %LAA-856exp percentage of lung attenuation area
with values <− 856 Hounsfield Units at expiratory CT scan, %pLDA percentage
of persistent low density area
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the Additional file 1). FEV1 differentiated NE from ME
with 0.62 sensitivity and 0.80 specificity (AUC 0.74) and
ME from SE with 0.77 sensitivity and 0.67 specificity
(AUC 0.77). Likewise, FEV1/FVC differentiated NE from
ME with 0.68 sensitivity and 0.88 specificity (AUC 0.83)
and ME from SE with 0.82 sensitivity and 0.76 specificity
(AUC 0.82).
The graph in Fig. 3a represents the ten folds averaged
ROC curve obtained by varying the classification thresh-
old over the range of the logistic regression model out-
put π = Pr (Y = “Severe” | X = ESI) for the probability of
“severe” emphysema (%LAA-950insp ≥14, data provided
by VIDA). The best results in terms of sensitivity and
specificity were relative to the threshold value 0.47, with
sensitivity = 0.82 and specificity = 0.87. The total AUC
area was of 0.88.
The graph in Fig. 3b represents the ten folds averaged
ROC curve obtained by varying the classification thresh-
old over the range of the logistic regression model out-
put π = Pr (Y = “Absence” | X = ESI) for the probability
of “absence” of emphysema (%LAA-950insp < 6, data pro-
vided by VIDA). The best results in terms of sensitivity
Table 4 Relationship among ESI values and functional data across the groups of patients with various degrees of emphysema
Emphysema severity N ESI score FEV1% FVC % FEV1/FVC % TLC % RV % FRC % DLco %
VIDA
NE 57 1.1 (1.5) 76.1 (23.6) 93.5 (22.8) 63.1 (8.0) 100.1 (11.8) 115.0 (30.5) 109.3 (18.2) 79.7 (22.9)
ME 58 3.1 (2.6) 63.6 (23.9) 91.4 (21.0) 54.1 (10.2) 106.9 (18.8) 134.1 (51.7) 125.3 (31.0) 75.6 (21.6)
SE 79 6.8 (2.5) 49.9 (23.7) 91.2 (27.8) 42.4 (10.8) 115.2 (15.1) 157.6 (48.2) 147.9 (33.7) 55.9 (19.8)
ANOVA / Welch’s test p <.001 <.001 .002 <.001 <.001 <.001 <.001 <.001
Imbio LDA
NE 86 1.5 (1.8) 72.6 (22.9) 92.9 (20.9) 60.5 (9.2) 101.1 (15.6) 118.2 (42.0) 111.5 (23.7) 78.9 (23.2)
ME 46 4.6 (2.7) 63.8 (27.5) 94.1 (25.2) 52.1 (10.1) 111.9 (15.0) 145.6 (47.4) 135.4 (30.5) 72.6 (18.1)
SE 62 7.7 (3.3) 44 (18.8) 88.6 (28.2) 39.6 (9.5) 115.7 (15.5) 160.7 (46.2) 152.1 (32.5) 51.9 (18.9)
ANOVA / Welch’s test p <.001 <.001 .442 <.001 <.001 <.001 <.001 <.001
CALIPER
G1 95 1.7 (2.1) 71.9 (23.7) 92.8 (21.9) 59.8 (9.6) 101.2 (14.6) 118.7 (39.4) 113.2 (24.3) 78.4 (23.2)
G2 65 5.4 (2.8) 59.7 (24.9) 97.1 (26.5) 48.8 (11.0) 113.4 (16.5) 145.9 (47.6) 137.9 (30.7) 65.6 (19.0)
G3 34 8.0 (1.7) 36.8 (14.3) 79.5 (23.2) 36.5 (8.0) 118.2 (13.6) 177.3 (44.0) 163.4 (29.9) 48.1 (18.5)
ANOVA / Welch’s test p <.001 <.001 .002 <.001 <.001 <.001 <.001 <.001
Differences among groups were assessed by analysis of variance and Welch’s tests, expressed in italics and in bold if significant. Values are expressed as mean
(SD). DLco % percent predicted diffusing lung capacity for carbon monoxide, FEV1% percent predicted forced expiratory volume in 1 s, FRC% percent predicted
functional residual capacity, FVC% percent predicted forced vital capacity, %LAA-950insp percentage of lung attenuation area with values <−950 Hounsfield Units at
inspiratory CT scan, ME (moderate emphysema, 6 ≤%LAA-950insp < 14 if VIDA or 6 ≤%pLDA < 14 if Imbio LDA), NE (no emphysema, %LAA-950insp < 6 if VIDA or
%pLDA < 6 if Imbio LDA), RV% percent predicted residual volume, SE (severe emphysema, %LAA-950insp ≥ 14 if VIDA or %LAA-950insp ≥ 14 if Imbio LDA), TLC%
percent predicted total lung capacity
Table 5 Post-hoc analysis of differences between groups with various degrees of emphysema as described in Table 4
ESI FEV1% FVC% FEV1/FVC% TLC% RV% FRC% DLco%
VIDA p NE/ME <.01 <.01 <.01 <.01 .28 <.01 <.01 <.01
p NE/SE <.01 <.01 <.01 <.01 <.01 <.01 <.01 <.01
p ME/SE <.01 <.01 .52 <.01 <.01 <.01 <.01 <.01
Imbio LDA p NE/ME <.01 .16 .96 <.01 <.01 <.01 <.01 .21
p NE/SE <.01 <.01 .56 <.01 <.01 <.01 <.01 <.01
p ME/SE <.01 <.01 .54 <.01 .42 .23 .02 <.01
CALIPER p G1/G2 <.01 <.01 .52 <.01 <.01 <.01 <.01 <.01
p G2/G3 <.01 <.01 <.01 <.01 .28 <.01 <.01 <.01
p G1/G3 <.01 <.01 <.01 <.01 <.01 <.01 <.01 <.01
Groups are defined according the classification performed by VIDA and Imbio LDA (NE, ME, SE) and by CALIPER (G1, G2, G3). Differences were analyzed by Games-
Howell post-hoc test and p values are displayed (significant p values are in bold). Legend: DLco % percent predicted diffusing lung capacity for carbon monoxide,
FEV1% percent predicted forced expiratory volume in 1 s, FRC% percent predicted functional residual capacity, FVC% percent predicted forced vital capacity,
%LAA-950insp percentage of lung attenuation area with values <−950 Hounsfield Units at inspiratory CT scan, ME (moderate emphysema, 6 ≤%LAA-950insp < 14 if
VIDA or 6 ≤%pLDA < 14 if Imbio LDA), NE (no emphysema, %LAA-950insp < 6 if VIDA or %pLDA < 6 if Imbio LDA), RV% percent predicted residual volume, SE
(severe emphysema, %LAA-950insp ≥ 14 if VIDA or %LAA-950insp ≥ 14 if Imbio LDA), TLC% percent predicted total lung capacity
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and specificity were relative to the threshold value 0.37,
with sensitivity = 0.80 and specificity = 0.85. The total
AUC area was of 0.86.
Therefore, NE is differentiated from ME/SE with a
sensitivity of 0.80 and a specificity of 0.85, whereas SE is
differentiated from ME with a sensitivity of 0.82 and a
specificity of 0.87 by using the MEFV curve.
Figure 4 shows differences in MEFV curves of two rep-
resentative subjects with severe emphysema and no em-
physema. The former has a flatter slope when flow is
plotted against expired volume but not at pletysmo-
graphic thoracic volume, indicating greater thoracic gas
compression at high-to-mid lung volumes.
Discussion
The extensive application of CT scan post-processing
techniques has shown that presence and severity of em-
physema as assessed by CT does closely reflect lung
function presentation in COPD. The main finding of this
study is that a mathematical model developed to fit the
descending limb of the MEFV curve approximates the
multimodality CT-validated emphysema stratification
with an accuracy that could be suitable for clinical and
research purposes. The model is based only on MEFV
curve morphology and, consequently, it is independent
from percentage predicted values of pulmonary function.
In recent years quantitative CT enabled radiologists to
quantify and localize the relative volumes of emphysema
and gas trapping in subjects with COPD by using standard
CT metrics of low attenuation areas at pre-determined in-
spiratory and expiratory X-ray attenuation thresholds [1,
17]. Beside CT quantification of emphysema, the new
computational radiomics approach allows to extract mul-
tiple features from imaging data and to process them in
order to objectively and reproducibly characterize the
main pathologic changes in the course of lung
diseases. Radiomics artificial intelligence can be used
to develop non-invasive imaging biomarkers, which
Fig. 3 ROC curve over the range of the ESI model output for severe
emphysema a and no emphysema b. Severe emphysema was
defined at CT scan as %LAA-950insp ≥ 14 by VIDA whereas no
emphysema was defined at CT scan as %LAA-950insp < 6 by VIDA. The
total AUC area was of 0.88 for severe emphysema and 0.86 for
no emphysema
Fig. 4 Maximal expiratory flow-volume curves of two representative subjects with severe emphysema or no emphysema. Patient with severe
emphysema (left panel) had %LAA-950insp = 24 whereas the patient with no emphysema (right panel) had %LAA-950insp = 4 at CT. Note the flatter
slope in the former when flow was plotted against expired volume (black lines) but not pletysmographic thoracic volume (grey lines), indicating
greater thoracic gas compression at high-to-mid lung volumes
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could be helpful in phenotyping heterogeneous dis-
eases, such as COPD [23].
As shown in Table 4, patients allocation in emphysema
severity subgroups varies with the different CT metrics
and radiomics approaches used. Despite this heterogen-
eity of classification reflecting the underlying methodo-
logical differences of the three CT post-processing
analyses, ESI differentiates the progressive severity of
emphysema whatever the CT method used to classify
patients. CT metrics of emphysema (%LAA-950insp and
%pLDA) correlated more strongly to ESI compared to
FEV1 and FEV1/FVC. These results support the useful-
ness of the MEFV curve in better depicting the emphy-
sema extent as assessed at CT, instead of the standard
functional variables (FEV1 and FEV1/FVC) used in clin-
ical practice.
A recent study from our group showed that a prob-
abilistic model including DLco%, FEV1%, FEV1/VC, and
BMI dissects with accuracy emphysematous from
non-emphysematous gas trapping as assessed by stand-
ard CT metrics in patients with COPD [9]. Reduction in
DLco is considered a marker of emphysema in subjects
with COPD [24]. However, measurement of DLco is not
widely performed and standard pulmonary function pa-
rameters have a wide inter-individual variability, even
after normalization for ethnicity, age, and body size [10].
In the current study we overcame these limitations by a
model depending only from MEFV curve morphology
that does not require normalization by reference equa-
tions and, being a mathematical model and not a prob-
abilistic one, it does not depend from regression
coefficients reflecting the characteristics of a training set.
A role for the MEFV curve in predicting the risk of
emphysema was introduced as early as 1976 by Saltzman
et al. [25]. They proposed that a kinging of the descend-
ing limb of the MEFV curve might represent a sign of
airway collapse reflecting the presence of emphysema
[25]. More recently the angle between two regression
lines fitted to the descending limb of the MEFV curve
resulted to be predictive of the presence of emphysema
on CT scan with good specificity but low sensitivity [26].
The kinking of MEFV curve in emphysema can be
interpreted on the grounds of the wave-speed theory
[27]. During forced expiration, alveolar pressure in-
creases and gas is compressed within the lung, thus re-
ducing lung volume and elastic recoil pressure. As a
result, driving pressure and distending pressure at choke
point decrease, thereby reducing maximal flow. As dem-
onstrated in a recent study, this effect may be magnified
in emphysema because of the abrupt fall of lung elastic
recoil at high lung volumes and the larger amount of gas
to be compressed [28]. The composite result of these
physical phenomena is a flattening the MEFV curve. By
contrast, the scooping of MEFV curve in COPD patients
with predominant conductive airway disease may reflect
a smooth decrease of lung elastic recoil and a transition
of the choke point towards the lung periphery with less
gas compression [29]. Mechanisms that may contribute
to the kinking of forced expiratory flow in emphysema
are a sudden airway narrowing due to sharp decrease in
lung elastic recoil and a sharp decrease of thoracic gas
compression from high-to-mid lung volumes [30].
Therefore, flattening of the MEFV curve from
high-to-mid lung volumes (Fig. 4) could be a predictor
of emphysema. At variance with the above quoted paper
on the analysis of the MEFV curve [26], the model pre-
sented here predicts presence and severity of emphy-
sema with a considerable level of accuracy.
This study has some limitations. First, it included a
relatively small number of white Caucasian subjects that
cannot be considered representative of the wide clinical
spectrum of COPD in the general population. However,
the distribution of CT metrics and their average values
were similar to those reported from the COPDGene
Study that included more than 10,000 subjects of two
different ethnicities [9, 31]. Second, the CT scans were
acquired without spirometric control of lung inflation
level during the acquisition. However, all subjects re-
ceived prior cautious instruction on how to perform the
respiratory maneuvers just before undergoing CT scan-
ning by dedicated personnel. Third, radiomics is very
sensitive to protocol acquisition parameters, algorithm
definitions, and image processing [23]. Lack of
standardization of these components severely hampers
reproducibility and comparability of results. In this study
all CT scans were acquired with the same protocol by
the same personnel in each study center, and after cali-
bration of CT scanner before each examination. Fourth,
models based on MEFV curve strictly depend on patient
effort during spirometry, as it affects the magnitude of
thoracic gas compression [32]. This is a major determin-
ant of the shape of the MEFV curve, particularly in sub-
jects with predominant emphysema [13]. However,
accurate technicians training could overcome this limita-
tion. Fifth, emphysema CT subtypes were not evaluated
in this study. Assessment of ESI in each emphysema
subtype would be an important subject for future stud-
ies, in particular to demonstrate if any specific subtype
could be predicted more accurately than others.
Conclusions
This study demonstrates that the presence of emphy-
sema and its severity in patients with COPD, as defined
on inspiratory-expiratory CT scan by standard metrics
and co-registration analysis, as well as by a computa-
tional unsupervised CT-based radiomics, can be accur-
ately estimated by a mathematical model based on
MEFV curve morphology. The model is independent
Occhipinti et al. Respiratory Research          (2019) 20:101 Page 9 of 11
from reference values and, if confirmed in larger popula-
tions of patients with COPD, it could be helpful in clin-
ical practice to personalize therapy, to select patients for
clinical and pharmacologic trials, and for the interpret-
ation of their results whenever spirometry is the only
available examination.
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